Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 44

Results For "DoP"

449 News Found

Delfi liquid biopsy shows promise for reducing lung cancer deaths
Biotech | August 23, 2021

Delfi liquid biopsy shows promise for reducing lung cancer deaths

When the Delfi technology was used as a pre-screen to determine if a low dose CT (LDCT), should be performed, the combined approach led to the detection of 90% of lung cancers, including 80% of stage I cancers


European Commission mandates InferVision AI to monitor Covid-19 variants
Digitisation | August 17, 2021

European Commission mandates InferVision AI to monitor Covid-19 variants

InferVision's AI applications have been developed to quickly and accurately analyse signs of pulmonary infections from regular chest CT images. These images are processed to indicate ground-glass opacity and high tissue density, which are key findings of viral pneumonia caused by the coronavirus


Researchers develop remote ultrasound imaging using robotic technology
Drug Approval | August 16, 2021

Researchers develop remote ultrasound imaging using robotic technology

The project is a collaboration between IIT Delhi and AIIMS


Tesis Labs and Personal Genome Diagnostics tie-up to advance cancer treatment
Digitisation | August 11, 2021

Tesis Labs and Personal Genome Diagnostics tie-up to advance cancer treatment

The aim is to create new genomics solutions that could combat cancer and advance market access


QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements
Drug Approval | August 10, 2021

QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements

QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab


Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests
Digitisation | August 10, 2021

Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests

Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection


We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
interviews | August 07, 2021

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.


Govt committed to recognise healthcare workers engaged in Covid-19
Policy | August 04, 2021

Govt committed to recognise healthcare workers engaged in Covid-19

Five seats reserved for Wards of COVID warriors in central MBBS admission


Abbott receives FDA clearance for its imaging tech using AI
Digitisation | August 04, 2021

Abbott receives FDA clearance for its imaging tech using AI

Ultreon 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using AI -


'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.
Interviews | June 10, 2021

'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.

In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview: